ETNB - NASDAQ

89bio, Inc.

ETNB·NASDAQ

$14.84

+0.0000%

HealthcareBiotechnology

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$2.20B

EPS-3.5100

P/E Ratio-2.23

Earnings Date11/06/2025

etnb

Gross Profit

Last Annual Value

-38.00K

3-Year CAGR

22%

5-Year CAGR

-17%

10-Year CAGR

-20%

Adjust for Inflation

89bio, Inc. Competitors Analysis of Gross Profit

ETNB · NASDAQ

Company	Gross Profit	CAGR 3Y	CAGR 5Y	CAGR 10Y
89bio, Inc. NASDAQ:ETNB	-38.00K	N/A	N/A	N/A
Agios Pharmaceuticals, Inc. NASDAQ:AGIO	42.51M	34.9%	N/A	N/A
Beam Therapeutics Inc. NASDAQ:BEAM	117.45M	-32.3%	N/A	N/A
Cogent Biosciences, Inc. NASDAQ:COGT	-4.62M	N/A	N/A	N/A
Denali Therapeutics Inc. NASDAQ:DNLI	-11.18M	N/A	N/A	N/A
ImmunityBio, Inc. NASDAQ:IBRX	112.53M	465.6%	160.7%	119.2%
Liquidia Corporation NASDAQ:LQDA	145.08M	115.0%	71.3%	28.0%
Ocular Therapeutix, Inc. NASDAQ:OCUL	45.25M	-5.2%	3.0%	41.1%
Arcus Biosciences, Inc. NYSE:RCUS	237.00M	26.5%	-9.2%	N/A
Recursion Pharmaceuticals, Inc. NASDAQ:RXRX	-46.27M	N/A	N/A	N/A

89bio, Inc. Fair Value Envelope

ETNB · NASDAQ

Our analysis suggests that ETNB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $14.84, this represents a potential HIDDEN relative to our calculated worth for 89bio, Inc..

HIDDEN

Intrinsic Value

Current Price: $14.84

Related Guides

Blog Categories

Continue your ETNB research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.